Low-certainty evidence suggests that off-label fluoxetine may decrease weight compared with placebo .
However , low-certainty evidence suggests an increase in the risk for dizziness , drowsiness , fatigue , insomnia and nausea following fluoxetine treatment
BACKGROUND Fluoxetine is a serotonin reuptake inhibitor indicated for major depression .
It is also thought to affect weight control : this seems to happen through appetite changes result ing in decreased food intake and normalisation of unusual eating behaviours .
However , the benefit-risk ratio of this off-label medication is unclear .
OBJECTIVES To assess the effects of fluoxetine for overweight or obese adults .
Predictors of response to amine-specific antidepressants.
Discriminant function analysis of data from a double-blind comparative trial of lofepramine ( a noradrenaline-specific reuptake inhibitor ) and fluoxetine ( a serotonin-specific reuptake inhibitor ) , involving 183 patients was used to identify predictors of response . Psychic anxiety significantly predicted a positive response to antidepressant medication , whereas psychomotor retardation , observed sadness , subjective lassitude and somatic complaints were significant predictors of nonresponse . Age , gender , endogenicity , duration of illness and number of previous episodes were not predictive of response . Significant differences were found between predictors of response to fluoxetine and lofepramine ( P < 0.001 all groups ) . Predictors of response to lofepramine were similar to overall predictors , i.e. , psychic anxiety predicted responders whilst observed sadness , psychomotor retardation , lassitude , inability to feel and somatic complaints predicted nonresponders . In contrast , baseline weight loss predicted response to fluoxetine , whereas anxiety , reduced insight and a tendency to blame others significantly predicted nonresponse . Such findings have practical implication s for the management of depressive illness
Low-certainty evidence suggests that off-label fluoxetine may decrease weight compared with placebo .
However , low-certainty evidence suggests an increase in the risk for dizziness , drowsiness , fatigue , insomnia and nausea following fluoxetine treatment
BACKGROUND Fluoxetine is a serotonin reuptake inhibitor indicated for major depression .
It is also thought to affect weight control : this seems to happen through appetite changes result ing in decreased food intake and normalisation of unusual eating behaviours .
However , the benefit-risk ratio of this off-label medication is unclear .
OBJECTIVES To assess the effects of fluoxetine for overweight or obese adults .